1. Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. (14th October 2018) Authors: Blauvelt, A.; Reich, K.; Lebwohl, M.; Burge, D.; Arendt, C.; Peterson, L.; Drew, J.; Rolleri, R.; Gottlieb, A.B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 3(2019) Page Start: 546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗